ProCyte Corporation Introduces Neova Therapy Dual Action Lotion; GHK Copper Peptide Complex + Retinol.

To download high-resolution, print-ready JPEG images, click on the thumbnail image above.

WARNING: these images are

very large (800K+)

Click here for caption

Business Editors

MULTIMEDIA AVAILABLE:

http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4589964

REDMOND, Wash.--(BUSINESS WIRE)--March 9, 2004

ProCyte Corporation (OTCBB:PRCY) announces the introduction of Neova(R) Therapy Dual Action Lotion which uses advanced nanoencapsulation technology to stabilize the combination of two anti-aging powerhouses, GHK Copper Peptide Complex(R) micronutrition and Retinol, into an intensive lightweight lotion. Copper is an essential component for collagen and elastin production, while providing a potent antioxidant defense against free radicals. Clinical studies have demonstrated the many benefits of GHK:Cu including decreased fine lines and wrinkles, decreased skin blotchiness and an increase in skin firmness and tone -- all without irritation! Retinol is a well-known and extensively studied skincare ingredient.

Looking good is a concern for all, especially aging baby-boomers. The aging process and photodamage cause the skin to thin and lines and wrinkles begin to develop. The body becomes slower to produce collagen, elastin and glycosaminoglycans. Age spots appear and skin becomes dull and lifeless as cell renewal slows and the skin's ability to retain moisture is diminished.

Scientific studies have shown that:

-- Copper plays an essential role in skin health by helping

restore the skin's ability to recover from damage.

-- Copper is a powerful collagen and elastin promoter, both

important for firm skin.

-- Copper works as an antioxidant by stimulating superoxide 

dismutase activity.

-- Copper is important in the production of glycosaminoglycans

(the cement that bonds tissue components together).

-- Copper-dependent enzymes increase the benefits of natural

tissue building processes.

Neova(R) Therapy Dual Action Lotion:

-- Nourishes skin with clinically proven GHK Copper Peptide

Complex(R) technology.

-- Retinol (pure Vitamin A) is gradually released to the skin,

minimizing potential for irritation.

-- Immediately helps to improve skin tone and texture.

-- Clinical studies using GHK Copper Peptide show a reduction in

fine lines and wrinkles.

-- Aloe Vera Gel and Vitamin E soothe and protect.

-- Leaves skin looking smooth and radiant.

"We are very excited about this product introduction into the physician market. Once again ProCyte is on the forefront of skincare product development with this new product," said Jack Clifford, president and CEO. "This product is the first of a series of new GHK copper peptide combination products being developed by ProCyte and covered by our new pending patent applications."

Neova(R) Therapy Dual Action Lotion is available in a 1 oz. bottle and can be purchased through leading dermatologists' and plastic surgeons' offices or online through leading medical skin care websites.

ProCyte Corporation develops and markets products based on its patented, clinically proven copper peptide technology for skin health, hair care and wound care. The Company sells directly to dermatologists, plastic and cosmetic surgeons, spas, and through licenses with strategic partners into the consumer market, including its long-term worldwide license agreement with Neutrogena(R), a Johnson & Johnson company. ProCyte's products include Neova(R), VitalCopper(TM), Simple Solutions(R) and AquaSante(R) Skin Care products; Complex Cu3(R) Post-Procedure Skin Care; GraftCyte(R) Hair Transplant Care; and Tricomin(R) Advanced Care for Thinning Hair. The Company also has the exclusive distribution rights for Cutanix Corporation's Quadrinone(R) technology for medical and spa markets in the U.S., Canada and Puerto Rico. Additional information is available by visiting the Company's website at www.procyte.com and www.vitalcopper.com.

This release may contain forward-looking statements relating to the research, development, commercialization, production, marketing and distribution of the Company's products and future operating results, which are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect the Company's actual results include its ability to develop, commercialize and produce new products; the market acceptance of existing and potential future products; the availability, cost and timely delivery of materials and services from and performance of third-party suppliers, manufacturers, distributors, licensees and other collaborative partners; the satisfaction of regulatory requirements, and the receipt, timing, terms and conditions of required regulatory approvals. Reference is made to the Company's Annual Report on Form 10-K for the year ended December 31, 2002 and its latest Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4589964